Biomedical

The new Life-Science company Celsus-Biomat B.V. is uniquely qualified to service the biomedical industry. The company combines know-how on heparin, heparin production, thrombosis, and biomaterials science. Celsus-Biomat B.V. will be licensed a proprietary antithrombotic agent for use as a bioactive component in drug eluting stents and other medical devices.....

More info

FlexGen B.V., is a spin-off from Dutch Space and Leiden University Medical Centre (LUMC) and develops instruments for flexible, high quality micro-array production. Their flagship product is the FlexArrayer. The FlexArrayer instrument allows researchers to easily and quickly design and synthesize custom micro-arrays. Which speedups the DNA research process.

More info

ACS Biomarker BV i.o. is spin-off from the University of Maastricht and the technology transfer organization BioMedbooster. ACS Biomarker, which is in the legal process of formation, is being established for the development and commercialization of cardiovascular biomarkers discovered at the Cardiovascular Research Institute of Maastricht University (CARIM).....

More info

MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory.
MUbio’s partnered and proprietary R&D projects focus on:....

More info

MagnaMedics is active in the field of developing and commercializing Nano tools and systems for Life Science Research, analytical laboratories, medical diagnostics and therapies. The start-up company possesses a proprietary IP portfolio and has a team, able to create new trends in NanoMedicine. Started in Aachen in 2003, MM GmbH opened its first subsidiary in Maastricht (NL) in december 2004.....

More info

Lead Pharma Holding BV. (LPH) is a spin off company of the Hubrecht Institute (Royal Dutch Academy of Sciences (KNAW)) and the University Medical Center Utrecht (UMCU). Lead Pharma Holding BV. (LPH) has the ownership of unique and highly representative human cell models, derived from heart restricted progenitor cells.....

More info